Kesios, a spin-out from Imperial College London, was developing a novel oncology therapeutic for multiple myeloma. Kesios could not replicate the pre-clinical assays of the inventor and the company suspended further development work.
Location: United Kingdom, England, London
Total raised: $28.4M
Investors 1
| Date | Name | Website |
| - | Abingworth... | abingworth... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.12.2015 | Series A | $28.4M | - |
Mentions in press and media 2
| Date | Title | Description |
| 02.12.2015 | Kesios Therapeutics Closes £19M Series A Financing | Kesios Therapeutics Ltd, a London, UK-based early-stage company developing novel therapeutics for the treatment of multiple myeloma and other cancers, closed a £19m (approx. $28.5m) Series A financing. Backers included Imperial Innovations ... |
| 08.10.2014 | Kesios Therapeutics Raises £1.85M in Seed Funding | Kesios Therapeutics, a London, UK-based oncology drug discovery company, raised £1.85m in seed funding. Imperial Innovations Group plc (AIM: IVO) made the investment and now holds a 48.4% stake in Kesios. The company is using the funds to a... |